Physician profile
Anna Mcmaster
NPI 1295429777
$4,963.09
in general payments reported to CMS, 2019-2025
29 companies · $1,999 in 2025
The $1,999 reported for 2025 was more than what 96% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $502 · 2024: $2,462 · 2025: $1,999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,895 · Education: $68.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,895.09 |
| Education | $68.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,367.85 | 2023-2025 | Interstim |
| Teleflex LLC | $611.13 | 2023-2025 | Urolift, Barrigel |
| Janssen Biotech, INC. | $449.26 | 2024-2025 | Erleada, Carvykti, Rybrevant |
| Sumitomo Pharma America, INC. | $305.39 | 2023-2025 | Orgovyx, Gemtesa |
| Astellas Pharma US INC | $283.16 | 2024-2025 | Xtandi |
| Coloplast Corp | $271.24 | 2025 | |
| Ferring Pharmaceuticals INC. | $187.52 | 2024-2025 | Adstiladrin |
| Dendreon Pharmaceuticals LLC | $155.72 | 2024-2025 | Provenge |
| Tolmar, INC. | $145.06 | 2024-2025 | Jatenzo, Rubraca, Eligard |
| Urogen Pharma, INC. | $142.11 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $140.69 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
| Bayer Healthcare Pharmaceuticals INC. | $112.76 | 2023-2024 | |
| Antares Pharma, INC. | $111.57 | 2024-2025 | Xyosted |
| Amgen INC. | $90.51 | 2025 | Krystexxa |
| Convatec INC. | $89.96 | 2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $87.72 | 2025 | Ams 700 |
| Endo Pharmaceuticals INC. | $70.25 | 2023-2024 | Aveed, Xiaflex |
| Abbvie INC. | $60.93 | 2024 | |
| Pfizer INC. | $58.70 | 2024-2025 | |
| Halozyme INC | $38.92 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $26.80 | 2025 | Lynparza |
| Tempus Ai, INC | $26.44 | 2025 | Xt Cdx |
| Endo USA, INC. | $22.80 | 2024 | Aveed, Xiaflex |
| Takeda Pharmaceuticals U.S.A., INC. | $22.54 | 2023 | Entyvio |
| Pharmaand Gmbh | $22.05 | 2025 | Rubraca |
| Abc Home Medical Supply, INC. | $19.95 | 2024 | |
| Olympus America INC. | $16.27 | 2025 | Itind System |
| Baxter Healthcare | $13.98 | 2023 | Floseal |
| Laborie Medical Technologies Corp. | $11.81 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Mcmaster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.